Sharemaestro Newsreel

MDLN News Today | Why did Medline stock go up today?

ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026

ResMed Inc. has filed its annual Form 10-K report with the U.S. SEC for the fiscal year ended June 30, 2026, detailing key corporate and financial information. The report confirmed that as of August 10, 2026, ResMed had 144,252,306 shares of Common Stock outstanding …

Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). …

MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who experienced significant financial losses. This investigation follows a June 2, 2026, FDA warning letter citing "significant violations" of manufacturing regulations …

RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary

ResMed Inc. reported strong fiscal year 2026 results, with net revenue climbing to $5.65 billion, a 9.9% increase year-over-year, and diluted EPS reaching $10.43. The company saw growth across all regions, driven by device and mask sales, and improved operational efficiencies led to a …

HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates

HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

Kaplan Fox is Investigating Medline Inc. (NASDAQ: MDLN) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm

Kaplan Fox & Kilsheimer LLP is investigating Medline Inc. (NASDAQ: MDLN) for potential securities law violations after the FDA issued a warning letter on June 2, 2026, citing significant violations of manufacturing regulations. This news caused Medline's stock to drop by 7.16%. The investigation …

Why Netflix Stock Popped Today

This article first appeared on GuruFocus. Bill Ackman (Trades, Portfolio)'s Pershing Square Capital Management has built a new position in Netflix (NASDAQ:NFLX), returning to the streaming company after a costly exit in 2022, according to a six-month financial report. Warning! GuruFocus has detected 2 …

Bill Ackman Buys Back Into Netflix Four Years After Selling at a Loss

This article first appeared on GuruFocus. Bill Ackman (Trades, Portfolio) disclosed six new holdings, buying Netflix (NASDAQ:NFLX), Visa (NYSE:V), Mastercard (NYSE:MA), eye care company Alcon (NYSE:ALC), exchange operator Intercontinental Exchange (NYSE:ICE) and financial data provider S&P Global (NYSE:SPGI) from the second quarter onward. The …

Align Climbs to No. 1,572 on the 2026 Inc. 5000

Align, a global provider of technology infrastructure solutions and Managed IT Services, has been named to the 2026 Inc. 5000 list for the third consecutive year, ranking at No. 1,572. This marks a significant advancement from its previous rankings, driven by increased demand for …

Becton, Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above …

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters …

Alcon terminates PowerVision IOL programs, takes $402M write-off

Alcon has terminated its PowerVision intraocular lens (IOL) programs after clinical study data revealed unpredictable postoperative outcomes, leading to a $402 million write-off in the second quarter. CEO David Endicott stated that the programs did not meet their visual performance and patient outcome standards. …

LENSAR Q2 Earnings Call Highlights

Key Points Interested in LENSAR, Inc.? Here are five stocks we like better. LENSAR's second-quarter revenue rose 18% to $16.5 million, driven by a 20% increase in recurring revenue to $13.7 million and a 23% increase in procedure revenue. GAAP net income reached $3.5 …

LENSAR, Inc. Q2 2026 Earnings Call Summary

LENSAR, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Reset and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Janus Henderson holds 11.1% of ICU Medical (ICUI) common stock via clients

Janus Henderson Group Ltd. has reported a beneficial ownership of 2,781,621 shares of ICU Medical, Inc. common stock, which constitutes 11.1% of the class. These shares are held through various Managed Portfolios where Janus Henderson's affiliated Asset Managers exercise investment and voting discretion, though …

GEHC or LMAT: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies …

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have added about 8.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings …

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

Revvity, Inc. launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed for small to mid-sized laboratories and clinics. This system aims to expand access to prenatal and preeclampsia testing with its ability to process up to 60 tests per hour …

Pershing Square H1 Earnings Call Highlights

Pershing Square (LON:PSH) held its first earnings call as Pershing Square Inc., with Chief Executive Officer and Chairman Bill Ackman outlining a strategy centered on long-term compounding in its existing investment vehicles, potential new fund launches and efforts to improve trading in Pershing Square …

Repligen Corporation (RGEN) Stock Forecasts

Argus has raised its target price for Repligen Corporation (RGEN) to $173.00. Repligen, a global life sciences company, specializes in developing bioprocessing equipment and supplies for manufacturing biologic drugs. The current stock price for RGEN is $167.49.

Earnings call transcript: SOLV Energy lifts 2026 outlook as revenue jumps in Q2 2026

Should Solventum’s (SOLV) Activist-Driven Asset Sales and HIS Separation Shift Its Capital Allocation Playbook?

Solventum (SOLV) recently announced slightly higher Q2 2026 results and confirmed that activist investor Trian Fund Management influenced its US$4.10 billion asset sale and plans to separate its Health Information Systems business. Management reiterated a focus on disciplined "tuck-in" acquisitions and a growing deal …

Intuitive Surgical (ISRG) Backs Long-Term Moat Amid Near-Term Volatility

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve …

How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds

ResMed (RMD) recently reported strong Q4 and full-year results, increasing its quarterly dividend to US$0.66 per share and completing a US$1.40 billion share buyback. However, the company also faces a softer outlook due to an FDA Class 1 recall of ventilators, suspending sales. This …

Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents

Femasys Inc. announced the issuance of new patents in the U.S. and internationally for the blended polymer component of its FemBloc non-surgical permanent birth control technology. These patents expand and strengthen the global intellectual property protection for FemBloc, complementing existing patents for its delivery …

EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Embecta Corp. (EMBC) for alleged violations of securities laws. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to …

ICU Medical Inc (ICUI) Chief Information Officer Ben Sousa Sells 2,250 Shares

ICU Medical Inc's Chief Information Officer, Ben Sousa, sold 2,250 shares of the company's stock for approximately $401,220. This transaction contributes to a trend of insider selling at the company, with 9 sells versus 2 buys over the last year. The stock is currently …

LeMaitre Vascular remains a Buy despite 31% pullback; strong organic growth and record margins support outlook.

LeMaitre Vascular's stock experienced a 31% drop after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages. However, the company demonstrates strong underlying demand with 10% organic sales growth and record-high margins, driven by its fastest-growing product, Artegraft. Despite the …

Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median?

Envista Holdings Corporation NVST is showing a sharper earnings recovery after a solid second quarter, with stronger profitability and raised 2026 guidance strengthening the near-term case. The offset is valuation. NVST now trades above its five-year median forward earnings multiple, leaving less room for …

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Omnicell, Inc. OMCL raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund. The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive …

Ackman adds Netflix, Visa and Mastercard in portfolio revamp

Investing.com -- Bill Ackman disclosed six new portfolio holdings on Thursday, including Netflix, Visa, and Mastercard, representing his largest portfolio restructuring in several years. The billionaire investor said he began purchasing the shares during the second quarter for his investment funds, including Pershing Square …